Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
ASX:IMR
Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$2.00
â–²(21.95% Upside)
Action:ReiteratedDate:02/27/26
The score is held down primarily by weak financial performance: collapsing revenue, negative gross profit, large losses, and significant ongoing cash burn alongside elevated debt. Technicals are comparatively supportive (price above major moving averages with neutral-to-positive momentum), but valuation is constrained by ongoing unprofitability and no dividend yield data.
Positive Factors
Niche, high-barrier product focus
Imricor’s focus on MR-conditional electrophysiology catheters and MRI-guided ablation positions it in a specialized niche with technical and regulatory complexity. This creates durable differentiation and higher switching costs for customers who adopt MRI-guided workflows.
Negative Factors
Persistent cash burn
Consistent, large negative operating and free cash flows indicate the business cannot self-fund operations or growth. Ongoing cash burn increases dependency on external financing, raising dilution and refinancing risk and constraining long-term investment in commercialization and R&D.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche, high-barrier product focus
Imricor’s focus on MR-conditional electrophysiology catheters and MRI-guided ablation positions it in a specialized niche with technical and regulatory complexity. This creates durable differentiation and higher switching costs for customers who adopt MRI-guided workflows.
Read all positive factors
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$587.33M
Dividend YieldN/A
Average Volume (3M)287.54K
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth-8.99%
EPS Growth-18.16%
CountryAU
Employees78
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.00
Shares Outstanding320,947,020
10 Day Avg. Volume240,875
30 Day Avg. Volume287,535
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.61Price Target Upside58.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$3.53M
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Company Description
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal prod...
How the Company Makes Money
Imricor’s revenue model is based on selling medical devices used in electrophysiology procedures. Key revenue streams include: (1) Sales of MRI-compatible ablation catheters and other disposable or procedure-specific consumables used during cardia...
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 302.50K | 959.42K | 615.57K | 816.01K | 696.27K |
| Gross Profit | -2.10M | -924.12K | -1.12M | -1.53M | -1.90M |
| EBITDA | -22.56M | -15.55M | -21.87M | -16.47M | -19.57M |
| Net Income | -26.20M | -29.69M | -22.63M | -17.53M | -20.56M |
Balance Sheet | |||||
| Total Assets | 45.79M | 21.62M | 8.31M | 13.70M | 26.86M |
| Cash, Cash Equivalents and Short-Term Investments | 40.81M | 15.71M | 831.52K | 5.69M | 18.52M |
| Total Debt | 26.62M | 21.35M | 10.42M | 4.45M | 1.74M |
| Total Liabilities | 34.26M | 29.00M | 17.06M | 6.19M | 4.46M |
| Stockholders Equity | 11.53M | -7.38M | -12.83M | 7.51M | 22.40M |
Cash Flow | |||||
| Free Cash Flow | -20.20M | -15.65M | -13.06M | -17.06M | -18.11M |
| Operating Cash Flow | -19.75M | -15.57M | -12.98M | -16.82M | -17.49M |
| Investing Cash Flow | -22.47M | -74.98K | -82.78K | -238.86K | -695.30K |
| Financing Cash Flow | 44.55M | 30.33M | 8.21M | 3.94M | 11.59M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Neutral
1.64
Price Trends
1.97
Negative
1.77
Positive
1.59
Positive
Market Momentum
-0.03
Positive
44.17
Neutral
41.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Neutral. The current price of 1.64 is below the 20-day moving average (MA) of 1.89, below the 50-day MA of 1.97, and above the 200-day MA of 1.59, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 41.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IMR.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$50.82M | -9.32 | -417.72% | ― | -34.06% | 75.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$587.33M | -12.03 | -109.63% | ― | -8.99% | -18.16% | |
45 Neutral | AU$30.58M | -1.41 | -165.13% | ― | 23.31% | -17.35% | |
44 Neutral | AU$96.64M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$144.52M | -10.00 | -70.29% | ― | ― | -257.32% | |
41 Neutral | AU$39.93M | -2.66 | -180.06% | ― | -14.25% | -22.83% |
* Healthcare Sector Average
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
1.83
0.36
24.49%
AU:IPD
Impedimed Limited
0.02
-0.02
-58.33%
AU:HMD
HeraMED Ltd.
0.04
0.03
193.33%
AU:CYC
Cyclopharm Limited
0.80
-0.30
-27.60%
AU:MX1
Micro-X Ltd.
0.06
>-0.01
-8.33%
AU:EMV
EMvision Medical Devices Ltd.
1.56
-0.24
-13.13%
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Targets U.S. Pediatric Market With FDA Bid for NorthStar Expansion
Apr 7, 2026
Imricor Medical Systems has submitted its NorthStar Mapping System to the U.S. Food and Drug Administration for a pediatric label expansion using the Special 510(k) pathway, building on its recent clearance for adult use. The move is central to th...
Imricor Sets Fully Virtual 2026 AGM as It Advances MRI-Guided Interventional Focus
Mar 26, 2026
Imricor Medical Systems, Inc., an ASX-listed medtech company, specializes in solutions that allow interventional procedures to be carried out under real-time MRI guidance rather than x-ray fluoroscopy, targeting improved safety, imaging quality, a...
Imricor lodges updated ASX corporate governance statement for 2025
Mar 26, 2026
Imricor Medical Systems has lodged its latest corporate governance statement with the ASX for the financial year ended 31 December 2025, confirming the document is current as of 27 March 2026 and approved by the board. The filing, accompanied by a...
Imricor Registers With U.S. SEC After Exceeding Shareholder Thresholds
Mar 18, 2026
Imricor Medical Systems has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission after surpassing shareholder thresholds that trigger mandatory registration under U.S. securities laws. The company stressed that t...
Imricor outlines FY 2025 investor presentation under strict disclosure and compliance caveats
Feb 24, 2026
Imricor Medical Systems has released its FY 2025 investor presentation, providing general background information on its operations, financial reporting framework and regulatory context for its ASX-listed CHESS Depositary Interests. The company emp...
Imricor Marks Pivotal Year as MRI-Guided Cardiac Platform Gains Regulatory and Commercial Traction
Feb 24, 2026
Imricor reported that FY2025 marked a pivotal year as it advanced its MRI-guided cardiac ablation platform with multiple second-generation products securing CE Mark approvals under the EU MDR and key components, including the Vision-MR Diagnostic ...
Imricor Widens Adjusted Loss as It Ramps Up Spending Ahead of U.S. and European Growth Push
Feb 24, 2026
Imricor Medical Systems reported a sharp decline in 2025 revenue to $292,309 from $959,424 a year earlier, driven by lower product sales as European customers shifted from commercial procedures to participation in the non‑revenue‑gener...
Imricor Seeks FDA 510(k) Clearance for Advantage-MR MRI-Guided EP System
Feb 5, 2026
Imricor Medical Systems has submitted its Advantage-MR electrophysiology (EP) Recorder/Stimulator system to the U.S. Food and Drug Administration for market clearance under the 510(k) pathway, a key step toward entering the U.S. market. The MR-con...
Imricor Adds Oklahoma Heart Institute as Fourth U.S. Site in VISABL-AFL Trial
Feb 2, 2026
Imricor Medical Systems has added Oklahoma Heart Institute as the fourth U.S. hospital site in its VISABL-AFL clinical trial, which is designed to support U.S. FDA approval of the company’s MRI-guided cardiac ablation products. Oklahoma Hear...
Imricor Wins Landmark FDA Clearance for MRI-Native NorthStar Mapping System
Jan 28, 2026
Imricor Medical Systems has secured U.S. FDA 510(k) clearance for its NorthStar Mapping System, the first and only MRI-native 3D mapping and guidance platform to receive such approval, marking its first capital equipment and software-centric produ...
Imricor Advances MRI-Guided Cardiac Ablation Platform Amid Clinical Milestones and Cash Burn
Jan 27, 2026
Imricor Medical Systems reported its fourth-quarter 2025 activities, highlighting a series of clinical and technological milestones that advance real-time MRI-guided cardiac ablation toward broader global adoption. The company announced the world&...
Imricor Adds Virginia Commonwealth University as Third U.S. Site in VISABL-AFL Trial
Jan 20, 2026
Imricor Medical Systems has secured Institutional Review Board approval for Virginia Commonwealth University Health to join its VISABL-AFL clinical trial, making VCU Health the third U.S. site participating in the study supporting U.S. FDA approva...
Imricor Options Lapse, Slightly Simplifying Capital Structure
Jan 14, 2026
Imricor Medical Systems Inc., an ASX-listed medical technology company focused on cardiac-related products, maintains its issued capital structure through various classes of securities, including options listed under the code IMRAJ. The company ha...
Imricor Issues 155,000 Unquoted Options Under Employee Incentive Plan
Jan 12, 2026
Imricor Medical Systems has notified the market of the issue of 155,000 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 1 January 2026. The new options, which will not be quoted on the...
Imricor Wins First FDA Clearance, Opening US Market for MRI-Guided EP Catheter
Jan 11, 2026
Imricor Medical Systems has received its first-ever clearance from the US Food and Drug Administration for the Vision-MR Diagnostic Catheter, an MRI-guided electrophysiology device that forms a key element of its MRI-compatible EP platform. The 51...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.